CO2021008535A2 - Compuestos de quinolina como inhibidores de quinasas tam y met - Google Patents

Compuestos de quinolina como inhibidores de quinasas tam y met

Info

Publication number
CO2021008535A2
CO2021008535A2 CONC2021/0008535A CO2021008535A CO2021008535A2 CO 2021008535 A2 CO2021008535 A2 CO 2021008535A2 CO 2021008535 A CO2021008535 A CO 2021008535A CO 2021008535 A2 CO2021008535 A2 CO 2021008535A2
Authority
CO
Colombia
Prior art keywords
tam
kinase inhibitors
met kinase
quinoline compounds
kinase
Prior art date
Application number
CONC2021/0008535A
Other languages
English (en)
Inventor
Adam Cook
Ronald Jay Hinklin
Oren T Mcnulty
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO2021008535A2 publication Critical patent/CO2021008535A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente, se proporcionan compuestos de la Fórmula I: I o sales de estos aceptables desde el punto de vista farmacéutico, en donde X1, X2, X3, R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente, que son inhibidores de una o más quinasas TAM y/o quinasa c-Met, y son útiles en el tratamiento y la prevención de enfermedades que se pueden tratar con un inhibidor de quinasa TAM y/o un inhibidor de quinasa c-Met.
CONC2021/0008535A 2019-01-03 2021-06-29 Compuestos de quinolina como inhibidores de quinasas tam y met CO2021008535A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962787965P 2019-01-03 2019-01-03
US201962858819P 2019-06-07 2019-06-07
US201962947720P 2019-12-13 2019-12-13
PCT/IB2020/050009 WO2020141470A1 (en) 2019-01-03 2020-01-02 Quinoline compounds as inhibitors of tam and met kinases

Publications (1)

Publication Number Publication Date
CO2021008535A2 true CO2021008535A2 (es) 2021-07-19

Family

ID=69185648

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008535A CO2021008535A2 (es) 2019-01-03 2021-06-29 Compuestos de quinolina como inhibidores de quinasas tam y met

Country Status (17)

Country Link
US (1) US20200216416A1 (es)
EP (1) EP3906234A1 (es)
JP (1) JP2022515880A (es)
KR (1) KR20210110664A (es)
CN (1) CN113302188A (es)
AU (1) AU2020205035A1 (es)
BR (1) BR112021012956A2 (es)
CA (1) CA3125559A1 (es)
CO (1) CO2021008535A2 (es)
CR (1) CR20210364A (es)
IL (1) IL284570A (es)
MA (1) MA54656A (es)
MX (1) MX2021008136A (es)
SG (1) SG11202106897XA (es)
TW (1) TWI745824B (es)
UY (1) UY38536A (es)
WO (1) WO2020141470A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019323455A1 (en) * 2018-08-24 2021-04-01 Transthera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CN116783166A (zh) * 2021-02-01 2023-09-19 江苏恒瑞医药股份有限公司 二甲酰胺类化合物、其制备方法及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
JP5314050B2 (ja) * 2008-01-23 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ４−ピリジノン化合物および癌についてのその使用
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
US10208034B2 (en) * 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019141202A1 (zh) * 2018-01-17 2019-07-25 南京药捷安康生物科技有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物

Also Published As

Publication number Publication date
JP2022515880A (ja) 2022-02-22
MA54656A (fr) 2022-04-06
US20200216416A1 (en) 2020-07-09
SG11202106897XA (en) 2021-07-29
CN113302188A (zh) 2021-08-24
CR20210364A (es) 2021-08-18
TW202039465A (zh) 2020-11-01
TWI745824B (zh) 2021-11-11
BR112021012956A2 (pt) 2021-10-26
MX2021008136A (es) 2021-08-11
KR20210110664A (ko) 2021-09-08
CA3125559A1 (en) 2020-07-09
IL284570A (en) 2021-08-31
WO2020141470A1 (en) 2020-07-09
EP3906234A1 (en) 2021-11-10
UY38536A (es) 2020-08-31
AU2020205035A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
DOP2019000090A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
DOP2019000091A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
DOP2022000117A (es) Inhibidores de kras g12c
CL2018000119A1 (es) Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret.
NI202100007A (es) COMPUESTOS DE PIRAZOLO[3, 4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
CO2019005287A2 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CO2022000266A2 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
AR107163A1 (es) Inhibidores de quinasa
DOP2021000090A (es) Compuestosy composicionespara el tratamientode afecciones asociadas con la actividad de nlrp